Health Care [ 6/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease.
The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab.
Immunovant, Inc. was founded in 2018 and is based in New York, New York.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 25 | -0.64 Decreased by -23.08% | -0.72 Increased by +10.73% |
| Feb 10, 25 | -0.76 Decreased by -111.11% | -0.75 Decreased by -1.02% |
| Nov 7, 24 | -0.74 Decreased by -64.44% | -0.60 Decreased by -23.33% |
| Aug 6, 24 | -0.60 Decreased by -5.26% | -0.53 Decreased by -13.21% |
| May 29, 24 | -0.52 Decreased by -13.04% | -0.43 Decreased by -20.93% |
| Feb 12, 24 | -0.36 Increased by +26.53% | -0.43 Increased by +16.28% |
| Nov 9, 23 | -0.45 Decreased by -9.76% | -0.47 Increased by +4.26% |
| Aug 10, 23 | -0.57 Decreased by -62.86% | -0.45 Decreased by -26.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 160.00 K Decreased by -89.33% | -106.45 M Decreased by -41.33% | Decreased by -66.53 K% Decreased by -1.22 K% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -111.12 M Decreased by -116.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -109.12 M Decreased by -86.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -87.15 M Decreased by -17.87% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 1.50 M Increased by +N/A% | -75.32 M Decreased by -26.73% | Decreased by -5.02 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -51.42 M Increased by +18.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -58.66 M Decreased by -22.40% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -73.94 M Decreased by -83.13% | Decreased by N/A% Decreased by N/A% |